GILEAD SCIENCES, INC. (GILD) is held by 6 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 5 funds trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $42.3M sold). 1 member of Congress reported 2 purchases vs 0 sales. Latest close $168.98 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 16, 2026 · Congress to Nov 16, 2026.
Dodge & Cox Funds · Ariel Investments · Edgewood Management — 6 tracked funds hold GILD. See all holders.
Insiders bought on the open market (0 purchases, $0) vs 37 sales ($42.3M). Insider trading 1 member of Congress reported buying (2 purchases vs 0 sales). Latest buy: May 6, 2026. Politician trading
GENERAL MILLS INC (GIS) · AMGEN INC (AMGN) · FREEPORT-MCMORAN INC (FCX) · 3M CO (MMM) · AT&T INC. (T) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Dodge & Cox Funds | 1.57% | 23,677,567 | TRIMMED (-2.4%) Q3 filed Nov 13 |
| Ariel Investments | 0.25% | 195,657 | TRIMMED (-3.3%) Q3 filed Nov 13 |
| Edgewood Management | 0.04% | 27,837 | HELD Q3 filed Nov 12 |
| DJE Kapital | 0.03% | 12,734 | TRIMMED (-92.2%) Q3 filed Nov 12 |
| Atalanta Sosnoff Capital | 0.01% | 2,548 | TRIMMED (-10.9%) Q3 filed Nov 10 |
| Mairs & Power Funds | <0.01% | 2,275 | HELD Q3 filed Nov 16 |
| OrbiMed Advisors | — | — | EXITED |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: +35.2% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
Tracked funds holding this stock, by quarter (2017Q1–2017Q1, 1 quarters). Source: quarterly BEST lists from 13F filings — tracked funds only, not all filers. A stock appears here only if it ever made a quarterly BEST list.
| Institutions holding | 2,280 of 8,857 filers |
| Long-only filers among them | 2,273 |
| Change vs 2026 Q1 | -10 net · 1,640 entered · 1,650 exited |
| Shares reported, all filers | 1,100,538,395 |
| Reported value, all filers | $134.8B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) (SIC 2836) |
| Revenue · FY2025 | $29.4B |
| Net income · FY2025 | $8.5B |
| Total assets · FY2025 | $59.0B |
| Shares outstanding | 1,239,955,155 |
| Market cap (at latest close) | $209.5B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 31, 2026.
| Shares short · Oct 15, 2026 | 20,270,007 |
| Share of shares outstanding | 1.63% |
| Days to cover | 3.72 |
Shares short at recent settlements — Jul 31, 2026: 24.4M · Aug 14, 2026: 23.2M · Aug 31, 2026: 23.0M · Sep 15, 2026: 18.3M · Sep 30, 2026: 21.8M · Oct 15, 2026: 20.3M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 31, 2026.
| Shares failed to deliver · Oct 14, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 2K · Sep 30, 2026: 0 · Oct 14, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 31, 2026.
0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 37 sales by 7 insiders ($42.3M).
Source: SEC Form 4 filings. Open-market transactions only.
Recent open-market trades
| Date | Insider | Role | Buy / Sell | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Nov 16, 2026 | Mercier Johanna | Chief Comm & Corp Aff Officer | Sell | 13,922 | $169.97 | $2.4M | SEC filing |
| Nov 16, 2026 | Mercier Johanna | Chief Comm & Corp Aff Officer | Sell | 13,178 | $171.09 | $2.3M | SEC filing |
| Nov 16, 2026 | Mercier Johanna | Chief Comm & Corp Aff Officer | Sell | 900 | $171.69 | $154.5K | SEC filing |
| Nov 16, 2026 | Dickinson Andrew D | Chief Financial Officer | Sell | 3,000 | $171.47 | $514.4K | SEC filing |
| Nov 12, 2026 | Kramer Kelly A. | Sell | 1,676 | $168.23 | $281.9K | SEC filing | |
| Nov 12, 2026 | Kramer Kelly A. | Sell | 3,800 | $169.44 | $643.9K | SEC filing | |
| Nov 12, 2026 | Kramer Kelly A. | Sell | 4,700 | $170.49 | $801.3K | SEC filing | |
| Nov 12, 2026 | Kramer Kelly A. | Sell | 200 | $171.44 | $34.3K | SEC filing | |
| Nov 6, 2026 | Cain Wettan Keeley M | EVP Gen Counsel, Legal & Comp | Sell | 3,399 | $164.11 | $557.8K | SEC filing |
| Nov 5, 2026 | O'Day Daniel Patrick | Chairman & CEO | Sell | 9,810 | $175.17 | $1.7M | SEC filing |
Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | JOHANNA MERCIER | Officer | 3,000 | $432.6K | Sep 15, 2026 | SEC filing |
| Sep 15, 2026 | ANDREW DICKINSON | Officer | 3,000 | $435.9K | Sep 15, 2026 | SEC filing |
| Aug 26, 2026 | ANTHONY WELTERS | Director | 18,000 | $2.7M | Aug 26, 2026 | SEC filing |
| Aug 20, 2026 | JEFFREY BLUESTONE | Director | 5,000 | $738.0K | Aug 20, 2026 | SEC filing |
| Aug 17, 2026 | JOHANNA MERCIER | Officer | 28,000 | $3.9M | Aug 17, 2026 | SEC filing |
| Aug 17, 2026 | ANDREW DICKINSON | Officer | 3,000 | $415.1K | Aug 17, 2026 | SEC filing |
| Aug 3, 2026 | DANIEL O'DAY | Director, Officer | 55,000 | $7.2M | Aug 3, 2026 | SEC filing |
| Jul 15, 2026 | JOHANNA MERCIER | Officer | 3,000 | $389.8K | Jul 15, 2026 | SEC filing |
| Jul 15, 2026 | ANDREW DICKINSON | Officer | 3,000 | $389.8K | Jul 15, 2026 | SEC filing |
| Jun 15, 2026 | ANDREW DICKINSON | Officer | 3,000 | $376.2K | Jun 15, 2026 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| Apr 29, 2026 | Vanguard Capital Management | SC 13G | 93,327,127 | 7.5% | Mar 31, 2026 | SEC filing |
| Mar 26, 2026 | The Vanguard Group | SC 13G/A | 0 | 0.0% | Mar 13, 2026 | SEC filing |
| Feb 5, 2026 | FMR LLC | SC 13G | 65,539,476.75 | 5.3% | Dec 31, 2025 | SEC filing |
| May 13, 2025 | Capital World Investors | SC 13G/A | 53,834,873 | 4.3% | Mar 31, 2025 | SEC filing |
| Apr 24, 2025 | BlackRock, Inc. | SC 13G/A | 101,739,273 | 8.2% | Mar 31, 2025 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
1 member of Congress reported buying (2 purchases vs 0 sales). Bought by Democrats. Latest buy: May 6, 2026.
Source: U.S. House Clerk and U.S. Senate eFD STOCK Act periodic transaction reports, as of Nov 16, 2026. Reported amounts are ranges, and reports can arrive up to 45 days after the trade.
Recent activity by member
| Member | Chamber | Party | Buys | Sells | Latest | Amount range |
|---|---|---|---|---|---|---|
| Moskowitz, Jared | House | D | 2 | 0 | May 6, 2026 | $1,001 - $15,000 |
Member-level activity in the current window, most recent first (House data to Nov 16, 2026, Senate to Oct 1, 2026). House reports arrive as PDFs without transaction-level rows in the current corpus, so this table shows per-member totals, not individual trades; the member page lists the underlying filings. Senate rows link the same way — the member page carries the eFD filing links.
Industry: Biological Products, (No Diagnostic Substances) (SIC 2836). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Lobbying: 681 Lobbying Disclosure Act filings named this company as client, 2004–2026; most common issues: Health Issues (527), Medicare/Medicaid (280), Budget/Appropriations (123).
Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).
Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.
Politicians
· Bought by Members — Last 6 months: bought by a member of the U.S. Congress
Financial Screens
· Buffett — Companies with high ROE sustained for more than a decade
· Graham — Sound finances and a long run of profits
· Lynch PEG — Cheap against its growth rate
· Dividend Growth — Dividends raised for more than 10 years
· Neff Total Return Ratio — Growth plus dividends divided by P/E is high
· Earnings Quality (Cash Conversion) — Profits that actually come back as cash
Chart Signals
· Monthly Uptrend — Price above its 12-month moving average
· Top Relative Strength — Top 20% of the universe by 6-month return
Key figures
· Buffett — Latest ROE: 37.6% · Years ROE ≥15% (of 10): 8 · 10-yr avg ROE: 25.8% · Latest net income: $8.5B
· Graham — Current ratio: 1.55 · Straight profitable years: 19 · Debt ratio: — · Latest net income: $8.5B
· Lynch PEG — P/E: 24.43 · 5-yr EPS growth: 132.4% · PEG: 0.18
· Dividend Growth — Dividend per share: 3.16 · Dividend yield: 1.9% · Straight dividend years: 11 · 10-yr dividend growth: 71.7%
· Neff Total Return Ratio — EPS growth: 132.4% · Dividend yield: 1.9% · P/E: 24.43 · Neff ratio: 5.50
· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 8.38 · Operating cash flow: $10.0B · Net income: $8.5B
· Bought by Members — Members buying: 1 · Buy txns: 2 · Sell txns: 0 · Latest buy: May 6, 2026
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
· Super-investor 13F BEST — appeared in 1 of the last 40 quarterly lists; latest 2017 Q1, ranked #49 of 50.
· Politician BEST — appeared in 2 of the last 20 quarterly lists; latest 2025 Q1, ranked #50 of 50.
| 13F signal (2021 Q3 – 2026 Q1) | Events | Win rate | Avg return | SPY | Excess |
|---|---|---|---|---|---|
| Heavy accumulation — 3+ tracked funds increased together | 6 | 66.7% | +7.5% | +0.6% | +6.8% |
Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.
Also held by the tracked funds that hold GILD — ranked by lift, the co-holding pattern described in Methodology: GENERAL MILLS INC (GIS) · AMGEN INC (AMGN) · FREEPORT-MCMORAN INC (FCX) · 3M CO (MMM) · AT&T INC. (T) · ISHARES RUSSELL 1000 VALUE E (IWD) · Palo Alto Networks Inc (PANW) · TRAVELERS COMPANIES, INC. (TRV).
Filings audit: every filing lens on GILEAD SCIENCES, INC. (GILD), scored — GetCoattail Research.
| Filed | Items | Source |
|---|---|---|
| Oct 29, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| Aug 4, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| May 20, 2026 | 1.01 Entry into a Material Definitive Agreement · 2.03 Creation of a Direct Financial Obligation · 8.01 Other Events · 9.01 Financial Statements and Exhibits | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
GENERAL MILLS INC (GIS) · Filings audit: every filing lens on GILEAD SCIENCES, INC. (GILD), scored · Practice timing on GILD
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.